Farmas USA

Yo tengo otra forma de diversificar, 86% en una y el 14% para 14 chicharros de varios sectores:))

GALE

Galena Biopharma (GALE) Offers Outlook for 2016; Expects to Meet Multiple Cancer Immunotherapy Milestones

several milestones upcoming for 2016:

The pivotal, Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study is fully enrolled and is expected to reach two key milestones in the first half of the year. In the first quarter, the trial should see the 70th patient event, which is defined as a recurrence or death from any cause. Once this occurs, the Independent Data Safety and Monitoring committee will evaluate the data and provide the company with the safety and futility interim analysis. This analysis is expected in the second quarter.
The company expects to initiate a Phase 2 trial in patients with Ductal Carcinoma in Situ (DCIS) in the first quarter. This trial is being run in partnership with the National Cancer Institute.
For the Phase 2b randomized, combination trial with NeuVax and trastuzumab, Galena expects to present interim safety data as well as patient immunology data on the A24 and A25 Human Leukocyte Antigen (HLA) status in the fourth quarter.

Galena’s second immuno-oncology program consists of two assets, GALE-301 and GALE-302, targeting folate binding protein receptor-alpha, a well-validated therapeutic target in ovarian cancer. Based on positive data from the clinical programs, Galena plans the following:

Initiate a randomized, Phase 2b trial in ovarian cancer in the second half of this year based upon promising data from two ongoing trials: the GALE-301 Phase 2a clinical trial and the GALE-301/GALE-302 Phase 1b trial.
Present GALE-301/302 booster data in the second quarter.
Present GALE-301 Phase 2a, two-year data in the fourth quarter.
-we begin to prepare for the potential submission of a Biologics License Agreement (BLA) for NeuVax.

http://www.streetinsider.com/Corporate+News/Galena+Biopharma+%28GALE%29+Offers+Outlook+for+2016%3B+Expects+to+Meet+Multiple+Cancer+Immunotherapy+Milestones/11215655.html

NVAX

Ahora a 6.96$ pero sólo 66k cromos

IDRA

Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015

El artículo dice que la quiere ver más madura antes de invertir en ella a pesar de su evolución.

-The FDA granted orphan drug designation for IMO-8400, Idera's compound that is being researched as a treatment for diffuse large B-cell lymphoma. Landing an orphan drug designation usually allows a company to earn tax credits or gain longer periods of marketing exclusivity if the drug finds its way to market.

-IMO-8400 is also being studied as a potential treatment for Dermatomyositis, a rare inflammatory muscle and skin disease. During the year, the company initiated a phase 2 clinical trial to study its usefulness in treating the disease.

-The company reported promising data from its ongoing Phase 1/2 clinical trial for IMO-8400 as a treatment for patients with relapsed or refractory Waldenström's Macroglobulinemia.

-Idera successfully completed a Phase 1 trial that demonstrated that IMO-9200, a compound that may be used to treat inflammatory bowel disease, was safe and well tolerated across all tested dosages.

-The company entered into a strategic clinical alliance with MD Anderson Cancer Center to advance research on IMO-2125, Idera's TLR9 agonist, which is being studied in the exciting field of immuno-oncology.

-Idera signed an agreement with pharma giant GlaxoSmithKline (NYSE:GSK) to identify third-generation antisense molecules to be used to treat renal disease. GlaxoSmithKline provided Idera with an initial payment of $2.5 million and set up potential milestones that could send another $100 million Idera's way. If the product's annual net sales exceed $500 million, GlaxoSmithKline will be on the hook to pay up to 5% in royalties

The company is also on pace to burn through nearly $50 million in cash in 2015, and with only $95 million on its books as of September, it's likely that it will have to raise capital in the next year or two.

http://www.fool.com/investing/general/2016/01/13/why-idera-pharmaceuticals-inc-shares-dropped-36-in.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article

ARNA, caballo desbocado +10%

NVAX cerrando el gap intradia en 6,64 ... el problema es que nos ha pillado el giro para abajo del IBB justo ahi ... a ver como acaba la cosa ...

NVAX

Joer qué rapidez, esto parece un semáforo estropeao, del verde al rojo sin pasar por el naranja :(

Joder no dan respiro, que cansino es esto.

NVAX